Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study. Issue 174 (February 2019)

• Record Type: Journal Article
• Authors: Projean, D.; Lalonde, S.; Morin, J.; Nogues, E.; Séguin, A.; Vincent, A.; Lafrance, J.P.; Masson, V.; Kassis, J.; Fafard, J.; Lordkipanidzé, M.
• Is Part Of: Thrombosis research. Issue 174(2019)
• Page Start: 48
• Page End: 50
• Publication Date: 2019-02
• Subjects: LMWHs low-molecular-weight heparins -- VTE venous thromboembolism -- CKD severe chronic kidney disease -- UFH unfractionated heparin -- eGFR estimated glomerular filtration rate -- LOQ limit of quantification -- BMI body mass index -- IQR interquantile range -- CKD-EPI Chronic Kidney Disease-Epidemiology Collaboration; Anticoagulant -- Bioaccumulation -- Kidney disease -- Prophylaxis -- Renal insufficiency -- Venous thromboembolism; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2018.11.031
• Languages: English
• ISSNs: 0049-3848

Abstract

Highlights: Accumulation of LMWH is a concern in severe chronic kidney disease (CKD). 28 subjects with severe CKD received prophylactic tinzaparin for up to 8 days. All had undetectable trough anti-Xa levels; half had undetectable peak levels. Prophylactic tinzaparin dosing didn't incur clinically significant bioaccumulation.